2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Disparities Research, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5098 A phase I study of venetoclax, dexamethasone, Bortezomib, and daratumumab (VDBD) for adolescent and young adult patients with relapsed or refractory T-cell acute lymphoblastic leukemia and lymphomas

Batool Al Qanber, MD, Zainab Zulqarnain2, Branko Cuglievan, MD3, David McCall, MD4, Amber Gibson, DO5, Cesar Nunez, MD6, Samanta Catueno, MD7, Miriam B. Garcia, DO8
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

 Background: T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) accounts for approximately 12–15% of pediatric acute lymphoblastic leukemia (ALL). Although contemporary frontline therapy achieves event-free survival approaching 85%, outcomes for relapsed or refractory (R/R) disease remain poor, with conventional salvage chemotherapy producing complete remission (CR) rates of only 20–40%, and long-term survival after relapse remains limited. Unlike B-cell ALL, where targeted immunotherapies have transformed outcomes, treatment options for R/R T-ALL/LBL remain limited, highlighting the need for novel therapeutic strategies.

Venetoclax, bortezomib, and daratumumab have each demonstrated encouraging activity in preclinical models and early-phase clinical studies of R/R T-ALL, while dexamethasone enhances venetoclax-mediated apoptosis. Together, these agents provide complementary mechanisms of action through induction of apoptosis, inhibition of NF-κB signaling, enhanced BCL-2 dependence, and CD38-directed immune cytotoxicity. The combination has also demonstrated an acceptable safety profile in prior clinical studies without evidence of overlapping toxicities. Collectively, these findings support prospective evaluation of venetoclax, dexamethasone, bortezomib, and daratumumab (VDBD) in adolescents and young adults (AYA) with R/R T-ALL/LBL. To our knowledge, this is the first prospective clinical trial evaluating the VDBD combination in AYA with R/R T-ALL/LBL.

Methods: This is a single-center, open-label, phase I clinical trial (NCT07513129) evaluating VDBD in AYAs with R/R T-ALL/LBL. Up to 18 patients will be enrolled.  Key eligibility criteria include age 12–39 years, histologically or cytologically confirmed R/R T-ALL/LBL, adequate performance status (Lansky/Karnofsky ≥60), and adequate hepatic, renal, and cardiac function. Patients will receive venetoclax, dexamethasone, bortezomib, and daratumumab at doses previously shown to be safe and tolerable in clinical studies. Treatment will be administered according to the study protocol until completion of planned therapy, disease progression, unacceptable toxicity, or withdrawal from the study. The primary objective is to evaluate the safety and tolerability of VDBD. The secondary objective is to conduct a preliminary assessment of efficacy based on patients’ responses to treatment.  The primary endpoints are the incidence of adverse events and serious adverse events.  Secondary endpoints include best overall response (BOR), overall response rate (ORR), composite complete remission rate (CRc), and duration of response (DOR). Overall survival (OS) and event-free survival (EFS) will be evaluated as exploratory endpoints.   Patients will be followed for 30 days after the end of treatment to monitor toxicity and for up to 2 years after completion of the study to assess survival.

The study is actively recruiting participants at The University of Texas MD Anderson Cancer Center, and accrual is ongoing.

 

ClinicalTrials.gov Identifier: NCT07513129.

 

 

 

Batool Al Qanber, MD: No relevant conflicts of interest to declare.